Pfizer: The Portfolio Transformation Is Gaining Momentum (NYSE:PFE)
· seekingalpha.com
Pfizer remains a Buy as its robust pipeline and strategic acquisitions drive portfolio adaptation ahead of the LOE cliff. Learn more about PFE stock here.
I've been researching companies in-depth for over a decade, from commodities like oil, natural gas, gold and copper to tech like Google or Nokia and many emergi...